High dose ARB better than low dose for CHF
In this trial of 3846 patients with class 2-4 systolic CHF (EF <40%) who were intolerant of ACE inhibitors, they were randomized to 50mg or 150mg of losartan. Those in the high dose group had a lower risk of death/CHF hospitalization than the low dose group, at a median of 4.7 years (43% vs 46%). Increasing the losartan dose of CHF patients produces a small but signficant reduction in CHF admission/deaths (abstract)
